Literature DB >> 18164841

Acute toxicity in definitive versus postprostatectomy image-guided radiotherapy for prostate cancer.

Jonathan C Cheng1, Timothy E Schultheiss, Khanh H Nguyen, Jeffrey Y C Wong.   

Abstract

PURPOSE: To assess the incidence of acute gastrointestinal (GI) and genitourinary (GU) injury and the dose-volume response in patients with clinically localized prostate cancer treated with image-guided radiotherapy using helical tomotherapy. METHODS AND MATERIALS: Between November 2004 and March 2007, 146 consecutive patients with localized prostate cancer were treated with helical tomotherapy at the City of Hope Medical Center. Of the 146 patients, 70 had undergone prostatectomy. Acute GI and GU toxicities were evaluated using the Radiation Therapy Oncology Group/European Organization for Research and Cancer of Medical scoring system. Events were scored for patients developing Grade 2 or greater morbidity within 90 days after the end of radiotherapy (RT). The dosimetric parameters included the minimal dose received by the highest 10%, 20%, 50%, 80%, and 90% of the target volume, the mean rectal dose, minimal rectal dose, maximal rectal dose, and the volume receiving > or =45, > or =65, and > or =70 Gy. These variables, plus the status of radical prostatectomy, hormonal therapy, RT techniques, and medical conditions, were included in a multivariate logistic regression analysis. A goodness-of-fit evaluation was done using the Hosmer-Lemeshow statistic.
RESULTS: A dose-response function for acute GI toxicity was elicited. The acute GI Grade 2 or greater toxicity was lower in the definitive RT group than in the postoperative RT group (25% vs. 41%, p <0.05). Acute GU Grade 2 or greater toxicity was comparable between the two groups. No grade 3 or greater complications were observed. No dosimetric variable was significant for GU toxicity. For acute GI toxicity, the significant dosimetric parameters were the minimal dose received by 10%, 20%, and 50% of the target volume and the mean rectal dose; the most predictive parameter was the minimal dose received by 10% of the target volume. The dose-modifying factor was 1.2 for radical prostatectomy.
CONCLUSION: The results of our study have shown that acute rectal symptoms are dose-volume related. Postprostatectomy RT resulted in a greater incidence of acute GI toxicity than did definitive RT. For postoperative RT, it would be prudent to use different dose-volume limits.

Entities:  

Mesh:

Year:  2007        PMID: 18164841     DOI: 10.1016/j.ijrobp.2007.09.043

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  13 in total

1.  Volumetric image-guided highly conformal radiotherapy of the prostate bed: Toxicity analysis.

Authors:  Gianluca Ingrosso; Alessandra Carosi; Daniela di Cristino; Elisabetta Ponti; Andrea Lancia; Alessandra Murgia; Claudia Bruni; Pasquale Morelli; Franca Pietrasanta; Riccardo Santoni
Journal:  Rep Pract Oncol Radiother       Date:  2016-11-24

2.  Costs of early adjuvant radiation therapy after radical prostatectomy: a decision analysis.

Authors:  T N Showalter; K A Foley; E Jutkowitz; C D Lallas; E J Trabulsi; L G Gomella; A P Dicker; L T Pizzi
Journal:  Ann Oncol       Date:  2011-06-09       Impact factor: 32.976

3.  Use of fractional dose-volume histograms to model risk of acute rectal toxicity among patients treated on RTOG 94-06.

Authors:  Susan L Tucker; Jeff M Michalski; Walter R Bosch; Radhe Mohan; Lei Dong; Kathryn Winter; James A Purdy; James D Cox
Journal:  Radiother Oncol       Date:  2012-06-05       Impact factor: 6.280

4.  Toxicity reduction required for MRI-guided radiotherapy to be cost-effective in the treatment of localized prostate cancer.

Authors:  Leif-Erik D Schumacher; Alan Dal Pra; Sarah E Hoffe; Eric A Mellon
Journal:  Br J Radiol       Date:  2020-08-12       Impact factor: 3.039

5.  Acute and late urinary toxicity following radiation in men with an intact prostate gland or after a radical prostatectomy: A secondary analysis of RTOG 94-08 and 96-01.

Authors:  Raymond H Mak; Daniel Hunt; Jason A Efstathiou; Niall M Heney; Christopher U Jones; Himu R Lukka; Jean-Paul Bahary; Malti Patel; Alexander Balogh; Abdenour Nabid; Mark H Leibenhaut; Daniel A Hamstra; Kevin S Roof; Robert Jeffrey Lee; Elizabeth M Gore; Howard M Sandler; William U Shipley
Journal:  Urol Oncol       Date:  2016-07-02       Impact factor: 3.498

6.  Report from the Radiation Therapy Committee of the Southwest Oncology Group (SWOG): Research Objectives Workshop 2008.

Authors:  Paul Okunieff; Lisa A Kachnic; Louis S Constine; Clifton D Fuller; Laurie E Gaspar; Daniel F Hayes; Jean Hooks; Clifton Ling; Frank L Meyskens; Philip A Philip; David Raben; Stephen R Smalley; Gregory P Swanson; Beverly A Teicher; Charles R Thomas; Bhadrasain Vikram; Michael J Zelefsky; Laurence H Baker
Journal:  Clin Cancer Res       Date:  2009-09-01       Impact factor: 12.531

7.  Acute toxicity in prostate cancer patients treated with and without image-guided radiotherapy.

Authors:  Suki Gill; Jessica Thomas; Chris Fox; Tomas Kron; Aldo Rolfo; Mary Leahy; Sarat Chander; Scott Williams; Keen Hun Tai; Gillian M Duchesne; Farshad Foroudi
Journal:  Radiat Oncol       Date:  2011-10-28       Impact factor: 3.481

8.  Postoperative radiotherapy for prostate cancer : Morbidity of local-only or local-plus-pelvic radiotherapy.

Authors:  Cora Waldstein; Wolfgang Dörr; Richard Pötter; Joachim Widder; Gregor Goldner
Journal:  Strahlenther Onkol       Date:  2017-09-19       Impact factor: 3.621

9.  A prospective comparison of acute intestinal toxicity following whole pelvic versus small field intensity-modulated radiotherapy for prostate cancer.

Authors:  Yeon Joo Kim; Jin-Hong Park; In-Ha Yun; Young Seok Kim
Journal:  Onco Targets Ther       Date:  2016-03-09       Impact factor: 4.147

Review 10.  Gaps between Evidence and Practice in Postoperative Radiotherapy for Prostate Cancer: Focus on Toxicities and the Effects on Health-Related Quality of Life.

Authors:  Hamid Raziee; Alejandro Berlin
Journal:  Front Oncol       Date:  2016-03-24       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.